Allecra: Secret weapon vs. bacteria
Allecra developing broad-spectrum solution to resistant Gram-negative bacteria
Allecra Therapeutic GmbHaims to develop a broad-spectrum solution to multidrug-resistant Gram-negative bacteria. The company will advance at least two preclinical compounds acquired from Orchid Chemicals & Pharmaceuticals Ltd., an Indian pharma, for a range of nosocomial infections.
Allecra raised €15 million ($19.6 million) in a series A round in April co-led by Edmond de Rothschild Investment Partners and Forbion Capital Partners, with participation by Orchid, EMBL Ventures and CEO Nicholas Benedict.
Benedict was CEO of Swiss women's health company Lumavita AG and, prior